dc.contributor.author | Javitt, Daniel C. | |
dc.contributor.author | Schoepp, Darryle | |
dc.contributor.author | Kalivas, Peter W. | |
dc.contributor.author | Volkow, Nora D. | |
dc.contributor.author | Zarate, Carlos | |
dc.contributor.author | Merchant, Kalpana | |
dc.contributor.author | Bear, Mark | |
dc.contributor.author | Umbricht, Daniel | |
dc.contributor.author | Hajos, Mihaly | |
dc.contributor.author | Potter, William Z. | |
dc.contributor.author | Lee, Chi-Ming | |
dc.date.accessioned | 2012-02-22T21:23:44Z | |
dc.date.available | 2012-02-22T21:23:44Z | |
dc.date.issued | 2011-09 | |
dc.date.submitted | 2011-06 | |
dc.identifier.issn | 1946-6242 | |
dc.identifier.issn | 1946-6234 | |
dc.identifier.uri | http://hdl.handle.net/1721.1/69162 | |
dc.description.abstract | The neurotransmitter glutamate is the primary excitatory neurotransmitter in mammalian brain and is responsible for most corticocortical and corticofugal neurotransmission. Disturbances in glutamatergic function have been implicated in the pathophysiology of several neuropsychiatric disorders—including schizophrenia, drug abuse and addiction, autism, and depression—that were until recently poorly understood. Nevertheless, improvements in basic information regarding these disorders have yet to translate into Food and Drug Administration–approved treatments. Barriers to translation include the need not only for improved compounds but also for improved biomarkers sensitive to both structural and functional target engagement and for improved translational models. Overcoming these barriers will require unique collaborative arrangements between pharma, government, and academia. Here, we review a recent Institute of Medicine–sponsored meeting, highlighting advances in glutamatergic theories of neuropsychiatric illness as well as remaining barriers to treatment development. | en_US |
dc.description.sponsorship | National Institute of Mental Health (U.S.) (grant R37MH49334) | en_US |
dc.description.sponsorship | National Institute of Mental Health (U.S.) (Intramural Research Program) | en_US |
dc.description.sponsorship | National Institute of Mental Health (U.S.) (R01DA03383) | en_US |
dc.description.sponsorship | National Institute of Mental Health (U.S.) (P50MH086385) | en_US |
dc.description.sponsorship | National Institutes of Health (U.S.) | en_US |
dc.description.sponsorship | FRAXA Research Foundation | en_US |
dc.description.sponsorship | Howard Hughes Medical Institute | en_US |
dc.description.sponsorship | Simons Foundation | en_US |
dc.language.iso | en_US | |
dc.publisher | American Association for the Advancement of Science | en_US |
dc.relation.isversionof | http://dx.doi.org/10.1126/scitranslmed.3002804 | en_US |
dc.rights | Creative Commons Attribution-Noncommercial-Share Alike 3.0 | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/ | en_US |
dc.source | PubMed Central | en_US |
dc.title | Translating Glutamate: From Pathophysiology to Treatment | en_US |
dc.type | Article | en_US |
dc.identifier.citation | Javitt, David C. et al. “Translating Glutamate: From Pathophysiology to Treatment.” Science Translational Medicine 3.102 (2011): 102mr2–102mr2. | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences | en_US |
dc.contributor.approver | Bear, Mark | |
dc.contributor.mitauthor | Bear, Mark | |
dc.relation.journal | Science Translational Medicine | en_US |
dc.eprint.version | Author's final manuscript | en_US |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
dspace.orderedauthors | Javitt, D. C.; Schoepp, D.; Kalivas, P. W.; Volkow, N. D.; Zarate, C.; Merchant, K.; Bear, M. F.; Umbricht, D.; Hajos, M.; Potter, W. Z.; Lee, C.-M. | en |
mit.license | OPEN_ACCESS_POLICY | en_US |
mit.metadata.status | Complete | |